Objective: To describe the clinical characteristics and outcome of Abiotrophia and Granulicatella infective endocarditis and compare them with Viridans group streptococci infective endocarditis. Methods: All patients in the International Collaboration on Endocarditis (ICE) - prospective cohort study (PCS) and the ICE-PLUS cohort were included (n = 8112). Data from patients with definitive or possible IE due to Abiotrophia species, Granulicatella species and Viridans group streptococci was analyzed. A propensity score (PS) analysis comparing the ABI/GRA-IE and VGS-IE groups according to a 1:2 ratio was performed. Results: Forty-eight (0.64%) cases of ABI/GRA-IE and 1,292 (17.2%) VGS-IE were included in the analysis. The median age of patients with ABI/GRA-IE was lower than VGS-IE (48.1 years vs. 57.9 years; p = 0.001). Clinical features and the rate of in-hospital surgery was similar between ABI/GRA-IE and VGS-IE (52.1% vs. 45.4%; p = 0.366). Unadjusted in-hospital death was lower in ABI/GRA-IE than VGS-IE (2.1% vs. 8.8%; p = 0.003), and cumulative six-month mortality was lower in ABI/GRA-IE than VGS-IE (2.1% vs. 11.9%; p<0.001). After PS analysis, in-hospital mortality was similar in both groups, but six-month mortality was lower in the ABI/GRA IE group (2.1% vs. 10.4%; p = 0.029). Conclusions: Patients with ABI/GRA-IE were younger, had similar clinical features and rates of surgery and better prognosis than VGS-IE.
Bibliographical noteFunding Information:
This work was supported by the Resident Award “Emili Letang”, granted by Hospital Clínic de Barcelona, Research, Innovation and Education Department to AT. JMM received a personal 80:20 research grant from the Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, during 2017–23.
JMM has received consulting honoraria and/or research grants from AbbVie, Bristol-Myers Squibb, Contrafect, Genentech, Jansen, Medtronic, MSD, Novartis, Gilead Sciences, and ViiV Healthcare, outside the submitted work. CWW is a founder of Predigen Inc, and has received honoraria and/or research grants from Roche Molecular Sciences, Biomerieux, Biofire, Giner, IDbyDNA, Janssen, and Sanofi, outside the submitted work. VHC has received consulting honoraria from UpToDate and Theravance, outside of the submitted work. All other authors: no conflicts.
© 2022 The British Infection Association
- Abiotrophia, Granulicatella
- Infective endocarditis
- International collaboration on endocarditis
- Viridans group streptococci
- Abiotrophia Granulicatella